Long-term exposure to magnetic fields and the risks of Alzheimer's disease and breast cancer: Further biological research

Pathophysiology

Volumn 16, Issue 2-3, 2009, Pages 149-156

  Davanipour, Zoreh ^a   Sobel, Eugene ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease (AD); Amyloid beta (A ); Extremely low frequency (ELF); Magnetic fields (MFs); Melatonin

Indexed keywords

AMYLOID BETA PROTEIN; DNA; ESTRADIOL; HYDROXYL RADICAL; MELATONIN; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BREAST CANCER; DNA DAMAGE; ELECTRICAL EQUIPMENT; ENVIRONMENTAL EXPOSURE; EQUIPMENT DESIGN; HEALTH HAZARD; HIGH RISK POPULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; LONG TERM EXPOSURE; MAGNETIC FIELD; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PUBLIC HEALTH; RADIATION EXPOSURE; RADIOFREQUENCY RADIATION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 67650708936     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2009.01.005     Document Type: Review

References (80)

1. Z. Davanipour, E. Sobel, Section 12: Magnetic Field Exposure: Melatonin Production; Alzheimer's Disease; Breast Cancer, in: C.F. Blackman, M. Blank, M. Kundi, C. Sage (Organizing Committee), BioInitiative Report: A Rationale for a Biologically-based Public Exposure Standard for Electromagnetic Fields (ELF and RF), 2007. URL: http://www.bioinitiative.org/report/docs/section_12.pdf.
2. BioInitiative Report: A Rationale for a Biologically-based Public Exposure Standard for Electromagnetic Fields (ELF and RF), 2007. URL: http://www.bioinitiative.org/report/index.htm.
3. Schernhammer E.S., and Hankinson S.E. Urinary melatonin levels and breast cancer risk. J. Natl. Cancer Inst. 97 (2005) 1084-1087
4. Schernhammer E.S., Berrino F., Krogh V., Secreto G., Micheli A., Venturelli E., Sieri S., Sempos C.T., Cavalleri A., Schünemann H.J., Strano S., and Muti P. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 100 (2008) 898-905
5. Sobel E., and Davanipour Z. Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease. Neurology 47 (1996) 1594-1600
6. Sobel E., Davanipour Z., Sulkava R., Erkinjuntti T., Wikstrom J., Henderson V.W., Buckwalter G., Bowman J.D., and Lee P.J. Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer's disease. Am. J. Epidemiol. 142 (1995) 515-524
7. Sobel E., Dunn M., Davanipour Z., Qian Z., and Chui H.C. Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure. Neurology 47 (1996) 1477-1481
8. Davanipour Z., Tseng C.-C., Lee P.-J., and Sobel E. A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers. BMC Neurol. 7 (2007) 13. http://www.biomedcentral.com/1471-2377/7/13
9. Mayeux R., Tang W.X., Jacobs D.M., Manly J., Bell K., Merchant C., Small S.A., Stern Y., Wisniewski H.M., and Mehta P.D. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 46 (1999) 412-416
10. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., and Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
11. Noonan C., Reif J., Burch J., Ichinose T.Y., Yost M.G., and K. Magnusson K. Relationship between amyloid β protein and melatonin metabolite in a study of electric utility workers. J. Occup. Environ. Med. 44 (2002) 769-775
12. Maestroni G.J.M. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. In: Heuther G., Kochen W., Simat T.J., and Steinhart H. (Eds). Tryptophan, Serotonin, and Melatonin: Basic Aspects and Applications (1999), Kluwer Academic/Plenum Publishers, New York 217-226
13. Reiter R.J., Tan D.-X., Qi W., Manchester L.C., Karbownik M., and Calvo J.R. Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol. Signals Recept. 9 (2000) 160-171
14. Pappolla M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L., Reiter R.J., Efthimiopoulos S., and Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. 17 (1997) 1683-1690
15. Pappolla M.A., Chyan Y.J., Poeggeler B., Bozner P., Ghiso J., LeDoux S.P., and Wilson G.L. Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. J. Pineal Res. 27 (1999) 226-229
16. Pappolla M.A., Simovich M.J., Bryant-Thomas T., Chyan Y.J., Poeggeler B., Dubocovich M., Bick R., Perry G., Cruz-Sanchez F., and Smith M.A. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J. Pineal Res. 32 (2002) 135-142
17. Shen Y.X., Wei W., and Xu S.Y. Protective effects of melatonin on cortico-hippocampal neurotoxicity induced by amyloid beta-peptide 25-35. Acta Pharmacol. Sin. 23 (2002) 71-76
18. Zatta P., Tognon G., and Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J. Pineal Res. 35 (2003) 98-103
19. Jang M.H., Jung S.B., Lee M.H., Kim C.J., Oh Y.T., Kang I., Kim J., and Kim E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett. 380 (2005) 26-31
20. Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., and Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J. Biol. Chem. 273 (1998) 7185-7188
21. Poeggeler B., Miravalle L., Zagorski M.G., Wisniewski T., Chyan Y.J., Zhang Y., Shao H., Bryant-Thomas T., Vidal R., Frangione B., Ghiso J., and Pappolla M.A. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Aβ peptide. Biochemistry 40 (2001) 14995-15001
22. Skribanek Z., Balaspiri L., and Mak M. Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J. Mass Spectrom. 36 (2001) 1226-1229
23. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., and Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 85 (2003) 1101-1108 (Erratum in: J. Neurochem. 86 (2003) 1312)
24. Feng Z., Chang Y., Cheng Y., Zhang B.L., Qu Z.W., Qin C., and Zhang J.T. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J. Pineal Res. 37 (2004) 129-136
25. Cheng X., and van Breemen R.B. Mass spectrometry-based screening for inhibitors of β-amyloid protein aggregation. Anal. Chem. 77 (2005) 7012-7015
26. Clapp-Lilly K.L., Smith M.A., Perry G., Harris P.L., Zhu X., and Duffy L.K. Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease. Neuroreport 12 (2001) 1277-1280
27. Feng Z., Qin C., Chang Y., and Zhang J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 40 (2006) 101-109
28. Quinn J., Kulhanek D., Nowlin J., Jones R., Pratico D., Rokach J., and Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 1037 (2005) 209-213
29. Clapp-Lilly K.L., Smith M.A., Perry G., and Duffy L.K. Melatonin reduces interleukin secretion in amyloid-beta stressed mouse brain slices. Chem. Biol. Interact. 134 (2001) 101-107
30. Shen Y.X., Xu S.Y., Wei W., Sun X.X., Liu L.H., Yang J., and Dong C. The protective effects of melatonin from oxidative damage induced by amyloid beta-peptide 25-35 in middle-aged rats. J. Pineal Res. 32 (2002) 85-89
31. Rosales-Corral S., Tan D.-X., Reiter R.J., Valdivia-Velazquez M., Martinez-Barboza G., Acosta-Martinez J.P., and Ortiz G.G. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J. Pineal Res. 35 (2003) 80-84
32. Lahiri D.K., Chen D., Ge Y.W., Bondy S.C., and Sharman E.H. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J. Pineal Res. 36 (2004) 224-231
33. Shen Y.X., W/Wei, Yang J., Liu C., Dong C., and Xu S.Y. Improvement of melatonin to the learning and memory impairment induced by amyloid beta-peptide 25-35 in elder rats. Acta Pharmacol. Sin. 22 (2001) 797-803
34. Weinstock M., and Shoham S. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J. Neural Transm. 111 (2004) 347-366
35. Tang F., Nag S., Shiu S.Y., and Pang S.F. The effects of melatonin and Ginkgo biloba extract on memory loss and choline acetyltransferase activities in the brain of rats infused intracerebroventricularly with beta-amyloid 1-40. Life Sci. 71 (2002) 2625-2631
36. Cardinali D.P., Furio A.M., and Reyes M.P. Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. Ann. NY Acad. Sci. 1057 (2005) 327-336
37. Srinivasan V., Pandi-Perumal S., Cardinali D., Poeggeler B., and Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav. Brain Funct. 2 (2006) 15 10.1186/1744-9081-2-15
38. Cheng Y., Feng Z., Zhang Q.Z., and Zhang J.T. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 27 (2006) 129-139
39. Wang J.Z., and Wang Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol. Sin. 27 (2006) 41-49
40. Wu Y.H., and Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal Res. 38 (2005) 145-152
41. Tan D.-X., Manchester L.C., Terron M.P., Flores L.J., and Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 42 (2007) 28-42
42. Peyrot F., and Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J. Pineal Res. 45 (2008) 235-246
43. Tan D.-X., Manchester L.C., Reiter R.J., Qi W.B., Karbownik M., and Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 9 (2000) 137-159
44. Reiter R.J., Tan D.-X., and Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech. Ageing Dev. 123 (2002) 1007-1019
45. Tan D.-X., Chen L.D., Poeggeler B., Manchester L.C., and Reiter R.J. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1 (1993) 57-60
46. Bromme H.J., Morke W., Peschke D., Ebelt H., and Peschke D. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J. Pineal Res. 29 (2000) 201-208
47. Reiter R.J., Tang L., Garcia J.J., and Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60 (1997) 2255-2271
48. Reiter R.J., Tan D.-X., Manchester L.C., and Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem. Biophys. 34 (2001) 237-256
49. Reiter R.J., Acuna-Castroviejo D., Tan D.-X., and Burkhardt S. Free radical-mediated molecular damage: mechanisms for the protective actions of melatonin in the central nervous system. Ann. NY Acad. Sci. 939 (2001) 200-215
50. Antolin I., Obst B., Burkhardt S., and Hardeland R. Antioxidative protection in a high-melatonin organism: The dinoflagellate Gonyaulax polydera is rescued from lethal oxidative stress by strongly elevated, but physiologically possible, concentrations of melatonin. J. Pineal Res. 23 (1997) 182-190
51. Kotler M., Rodriguez C., Sainz R.M., Antolin I., and Menendez-Pelaez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J. Pineal Res. 24 (1998) 83-89
52. Pablos M.I., Chuang J.I., Reiter J.R., Ortiz G.G., Daniels W.M., Sewerynek E., Melchiorri D., and Poeggeler B. Time course of melatonin-induced increase in glutathione peroxidase activity in chick tissues. Biol. Signals 4 (1995) 325-330
53. Barlow-Walden L.R., Reiter R.J., Abe A., Pablos M., Menendez-Pelaez A., Chen L.D., and Poeggeler B. Melatonin stimulated brain glutathione peroxidase activity. Neurochem. Int. 26 (1995) 497-502
54. Montilla P., Tunez I., Munoz M.C., Soria J.V., and Lopez A. Antioxidative effect of melatonin in rat brain oxidative stress induced by Adriamycin. Rev. Esp. Fisiol. 53 (1997) 301-305
55. Vijayalaxmi, Reiter R.J., and Meltz M.L. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat. Res. 346 (1995) 23-31
56. Vijayalaxmi, Reiter R.J., Herman T.S., and Meltz M.L. Melatonin and radioprotection from genetic damage: DNA damage in human blood lymphocytes. Mutat. Res. 371 (1996) 221-228
57. Vijayalaxmi, Reiter R.J., Meltz M.L., and Herman T.S. Melatonin: possible mechanisms involved in its "radioprotective" effect. Mutat. Res. 404 (1998) 187-189
58. Pieri C., Marra M., Moroni F., Recchioni R., and Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci. 55 (1994) 271-276
59. Tamarkin L., Cohen M., Roselle D., Reichert C., Lippman M., and Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 41 (1981) 4432-4436
60. Shah P.N., Mhatre M.C., and Kothari L.S. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rates in varying photoperiods. Cancer Res. 44 (1984) 3403-3407
61. Kothari L.S., Shah P.N., and Mhatre M.C. Pineal ablation in varying photoperiods and the incidence of 9,10-dimethyl-1,2-benzathracene induced mammary cancer in rats. Cancer Lett. 22 (1984) 99-102
62. Subramanian A., and Kothari L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs 2 (1991) 297-303
63. Subramanian A., and Kothari L. Melatonin, a suppressor of spontaneous murine mammary tumors. J. Pineal Res. 10 (1991) 136-140
64. Tan D.-X., Poeggeler B., Reiter R.J., Chen L.D., Chen S., Manchester L.C., and Barlow-Walden L.R. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 70 (1993) 65-71
65. Tan D.-X., Reiter R.J., Chen L.D., Poeggeler B., Manchester L.C., and Barlow-Walden L.R. Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 15 (1994) 215-218
66. Teplitzky S.R., Kiefer T.L., Cheng Q., Dwivedi P.D., Moroz K., Myers L., Anderson M.B., Collins A., Dai J., Yuan L., Spriggs L.L., Blask D.E., and Hill S.M. Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett. 26 (2001) 155-163
67. Eck-Enriquez K., Kiefer T.L., Spriggs L.L., and Hill S.M. Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 61 (2000) 229-239
68. Karbownik M., Reiter R.J., Cabrera J., and Garcia J.J. Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat. Res. 474 (2001) 87-92
69. Blickenstaff R.T., Brandstadter S.M., Reddy S., and Witt R. Potential radioprotective agents. 1. Homologues of melatonin. J. Pharm. Sci. 83 (1994) 216-218
70. Vijayalaxmi, Meltz M.L., Reiter R.J., Herman T.S., and Kumar K.S. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat Res. 425 (1999) 21-27
71. Karbownik M., Reiter R.J., Qi W., Garcia J.J., Tan D.X., Manchester L.C., and Vijayalaxmi. Protective effects of melatonin against oxidation of guanine bases in DNA and decreased microsomal membrane fluidity in rat liver induced by whole body ionizing radiation. Mol. Cell. Biochem. 211 (2000) 137-144
72. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12 (1991) 151-158
73. Tan D.-X., Manchester L.C., Reiter R.J., Qi W.B., Karbownik M., and Calvo J.R. Significance of melatonin in antioxidant defense system: reactions and products. Biol. Signals Recept. 9 (2000) 137-159
74. Hardeland R., Blazer I., Poeggeler B., Fuhrberg B., Uria H., Behrmann G., Wolf R., Meyer T.J., and Reiter R.J. On the primary functions of melatonin in evolution: Mediation of photoperiodic signals in a unicell, photooxidation and scavenging of free radicals. J. Pineal Res. 18 (1995) 104-111
75. Stasica P., Ulanski P., and Rosiak J.M. Melatonin as a hydroxyl radical scavenger. J. Radioanal. Nucl. Chem. 232 (1998) 107-113
76. Halliwell B., and Gutteridge J.M. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246 (1986) 501-514
77. Tan D.-X., Manchester L.C., Reiter R.J., and Plummer B.F. Cyclic 3-hydroxymelatonin: a melatonin metabolite generated as a result of hydroxyl radical scavenging. Biol. Signals Recept. 8 (1999) 70-74
78. Wu Y.H., Feenstra W.G., Zhou J.N., Liu R.Y., Toranõ J.S., Van Kan H.J., Fischer D.F., Ravid R., and Swaab D.F. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 88 (2003) 5898-5906
79. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
80. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., and Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355 (2006) 2652-2663